Drug intelligence / Profile preview

FDgard

Development stage: Unknown
Lead developer: Nestlé Health Science
Modality: Small Molecules
Administration: Oral

Overview

FDgard is a medical food/dietary supplement specifically formulated for the dietary management of functional dyspepsia (FD) and meal-triggered indigestion. It contains a combination of caraway oil and l-Menthol, delivered via a patented Site-Specific Targeting (SST) technology. This technology utilizes triple-coated microspheres to ensure the active herbal ingredients are released in the upper digestive tract (duodenum), where they work to relax the smooth muscles of the stomach and improve gastric accommodation. Developed by Nestlé Health Science, FDgard is intended to manage symptoms such as bloating, nausea, early satiety, and upper abdominal pain.

Brand names: FDgard
Other names: caraway oil + l-Menthol

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)CaV (Voltage-gated calcium channel protein complex)

Beyond the preview

Go deeper on FDgard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FDgard.